CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: N4BP2L2 (ImmuneEditome ID:10443)

1. Gene summary of enriched editing regions for N4BP2L2

check button Gene summary
Gene informationGene symbol

N4BP2L2

Gene ID

10443

GeneSynonyms92M18.3|CG005|CG016|PFAAP5
GeneCytomap

13q13.1

GeneTypeprotein-coding
GeneDescriptionNEDD4-binding protein 2-like 2|phosphonoformate immuno-associated protein 5|protein from BRCA2 region
GeneModificationdate20230415
UniprotIDA0A6I8PRV3;B4DPY1;Q92802;A0A6I8PS46;A0A6I8PRM1;A0A6I8PRY6;A0A6I8PRR5;A0A6I8PRX5;A0A6I8PL95;A0A6I8PL40;D6R968;A0A6I8PRE0;A0A6I8PRI0;A0A6I8PRR0;A0A6I8PU16;A0A6I8PRT3;A0A6I8PRP6
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr13:32465745-32466534:-ENST00000380121.6ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,L1ME3D,MER112,AluSgchr13:32465745-32466534:-.alignment
chr13:32465745-32466534:-ENST00000473025.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,L1ME3D,MER112,AluSgchr13:32465745-32466534:-.alignment
chr13:32465745-32466534:-ENST00000503296.5ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,L1ME3D,MER112,AluSgchr13:32465745-32466534:-.alignment
chr13:32465745-32466534:-ENST00000509076.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,L1ME3D,MER112,AluSgchr13:32465745-32466534:-.alignment
chr13:32487948-32489060:-ENST00000473025.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx,AluSp,MIR,(TATGTA)n,L1PA16chr13:32487948-32489060:-.alignment
chr13:32487948-32489060:-ENST00000503296.5ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx,AluSp,MIR,(TATGTA)n,L1PA16chr13:32487948-32489060:-.alignment
chr13:32487948-32489060:-ENST00000509076.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx,AluSp,MIR,(TATGTA)n,L1PA16chr13:32487948-32489060:-.alignment
chr13:32492966-32494556:-ENST00000473025.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,AluYm1,MamRTE1,MIR3,AluSzchr13:32492966-32494556:-.alignment
chr13:32492966-32494556:-ENST00000509076.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,AluYm1,MamRTE1,MIR3,AluSzchr13:32492966-32494556:-.alignment
chr13:32500888-32503139:-ENST00000473025.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,AluY,MIRb,AluSx,L3,AluSzchr13:32500888-32503139:-.alignment
chr13:32500888-32503139:-ENST00000509076.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,AluY,MIRb,AluSx,L3,AluSzchr13:32500888-32503139:-.alignment
chr13:32510517-32510790:-ENST00000473025.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSxchr13:32510517-32510790:-.alignment
chr13:32510517-32510790:-ENST00000509076.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSxchr13:32510517-32510790:-.alignment
chr13:32514541-32516066:-ENST00000473025.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,AluSx,FLAM_C,AluJr4chr13:32514541-32516066:-.alignment
chr13:32514541-32516066:-ENST00000509076.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluSx1,AluSx,FLAM_C,AluJr4chr13:32514541-32516066:-.alignment
chr13:32523220-32523647:-ENST00000503814.1ENSG00000244754.7N4BP2L2ncRNA_exonicAluSz6,AluSg7chr13:32523220-32523647:-.alignment
chr13:32524776-32525685:-ENST00000503814.1ENSG00000244754.7N4BP2L2ncRNA_exonicAluJbchr13:32524776-32525685:-.alignment
chr13:32532627-32533756:-ENST00000475731.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluJo,AluSc,AluJr,L1M5chr13:32532627-32533756:-.alignment
chr13:32532627-32533756:-ENST00000511143.4ENSG00000244754.7N4BP2L2ncRNA_intronicAluJo,AluSc,AluJr,L1M5chr13:32532627-32533756:-.alignment
chr13:32532627-32533756:-ENST00000512755.1ENSG00000244754.7N4BP2L2ncRNA_intronicAluJo,AluSc,AluJr,L1M5chr13:32532627-32533756:-.alignment


Top

2. Tumor-specific enriched editing regions for N4BP2L2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr13:32524776-32525685:-BRCAEER1.1593e-05image
ENSG00000244754.7,N4BP2L2KIRCEAG6.1974e-03image
chr13:32524776-32525685:-LUSCEER3.4069e-03image
chr13:32524776-32525685:-THCAEER8.2991e-04image
ENSG00000244754.7,N4BP2L2THCAEAG1.6032e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000244754.7,N4BP2L2OVCliEAG2.0083e-032.7538e-030.1802image
chr13:32524776-32525685:-THCAPathEER3.7292e-021.8508e-020.1264image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr13:32524776-32525685:-LAMLEER3.9562e-024.4037e-029.6237e+01image

Top

3. Enriched editing regions and immune related genes for N4BP2L2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr13:32524776-32525685:-STADEERENSG00000164405,UQCRQ0.36298.7138e-082.2727e-130.4017imageNCSTF2T;TAF15NAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr13:32524776-32525685:-STADEERENSG00000127540,UQCR110.29173.7451e-056.6367e-140.4098imageNCSTF2T;TAF15NAT_cells_CD8GSVA_HALLMARK_MITOTIC_SPINDLE
chr13:32524776-32525685:-STADEERENSG00000103254,FAM173A0.22942.1214e-036.7535e-140.4097imageNCSTF2T;TAF15NAT_cells_CD8GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr13:32524776-32525685:-STADEERENSG00000169136,ATF50.17642.5759e-028.2835e-180.4635imageNCSTF2T;TAF15ATF5T_cells_follicular_helperGSVA_HALLMARK_DNA_REPAIR
chr13:32524776-32525685:-ESCAEERENSG00000171466,ZNF562-0.53379.6844e-082.4067e-10-0.4795imageNCSTF2T;TAF15NANK_cells_restingGSVA_HALLMARK_DNA_REPAIR
chr13:32524776-32525685:-ESCAEERENSG00000114933,INO80D-0.43838.8981e-051.3130e-08-0.4357imageNCSTF2T;TAF15NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr13:32524776-32525685:-ESCAEERENSG00000143314,MRPL240.42441.6065e-045.0077e-090.4468imageNCSTF2T;TAF15NAMacrophages_M1GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr13:32524776-32525685:-ESCAEERENSG00000173207,CKS1B0.40502.2756e-041.0006e-080.4388imageNCSTF2T;TAF15NADendritic_cells_activatedGSVA_HALLMARK_E2F_TARGETS
chr13:32524776-32525685:-ESCAEERENSG00000160688,FLAD10.41352.4822e-042.6171e-090.4541imageNCSTF2T;TAF15NAMast_cells_restingGSVA_HALLMARK_MYC_TARGETS_V2
chr13:32524776-32525685:-ESCAEERENSG00000163382,APOA1BP0.41003.6854e-046.5333e-090.4438imageNCSTF2T;TAF15NAMast_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

4. Enriched editing regions and immune related splicing for N4BP2L2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr13:32524776-32525685:-
ESCAEERIRENSG00000163479.9chr1156011809:156012565:156014960:156015069-0.37342.9393e-037.6365e-08-0.4426imageNCSTF2T;TAF15NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr13:32524776-32525685:-
ESCAEERIRENSG00000090238.7chr1630095251:30095434:30096096:30096170-0.38433.8808e-031.0179e-07-0.4106imageNCSTF2T;TAF15NADendritic_cells_restingGSVA_HALLMARK_APICAL_SURFACE
chr13:32524776-32525685:-
ESCAEERIRENSG00000120963.7chr8101202332:101202447:101204649:101204693-0.28323.3695e-022.8647e-06-0.4092imageNCSTF2T;TAF15NAGSVA_HALLMARK_DNA_REPAIR
chr13:32524776-32525685:-
ESCAEERIRENSG00000244754.4chr1332521372:32521449:32522181:32522270-0.38912.9625e-036.7630e-08-0.4157imageNCSTF2T;TAF15NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
chr13:32524776-32525685:-
ESCAEERIRENSG00000143774.12chr1228140227:228140363:228141123:228141288-0.40771.4924e-034.2766e-08-0.4227imageNCSTF2T;TAF15NAT_cells_CD4_memory_restingGSVA_HALLMARK_DNA_REPAIR
chr13:32524776-32525685:-
ESCAEERIRENSG00000172009.10chr192809845:2810098:2810303:2810481-0.29572.3528e-023.2950e-06-0.4166imageNCSTF2T;TAF15THOP1T_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
chr13:32524776-32525685:-
ESCAEERIRENSG00000071626.12chr191416456:1416555:1417499:1417540-0.31912.3913e-026.7752e-07-0.4080imageNCSTF2T;TAF15NAMacrophages_M2GSVA_HALLMARK_E2F_TARGETS
chr13:32524776-32525685:-
ESCAEERIRENSG00000134453.11chr106112589:6113068:6113507:6113581-0.36621.0679e-021.3677e-07-0.4092imageNCSTF2T;TAF15NAMacrophages_M2GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr13:32524776-32525685:-
ESCAEERIRENSG00000129197.10chr175425970:5428211:5432541:5432608-0.42956.9978e-041.6200e-07-0.4046imageNCSTF2T;TAF15NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
chr13:32524776-32525685:-
ESCAEERIRENSG00000143933.12chr247172413:47172459:47176440:47176511-0.32742.4450e-021.2861e-07-0.4216imageNCSTF2T;TAF15NAB_cells_memoryGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for N4BP2L2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000244754.7,N4BP2L2ACCEAGB_cells_naive4.5731e-03-0.5694image
chr13:32514541-32516066:-BLCAEERT_cells_CD4_naive1.2516e-030.5698image
chr13:32524776-32525685:-BLCAEERB_cells_naive1.9308e-020.1941image
ENSG00000244754.7,N4BP2L2BLCAEAGMacrophages_M07.0386e-030.1986image
chr13:32524776-32525685:-BRCAEERMast_cells_resting6.9610e-04-0.1232image
ENSG00000244754.7,N4BP2L2BRCAEAGT_cells_follicular_helper4.6344e-040.1232image
chr13:32524776-32525685:-CESCEERT_cells_CD4_memory_resting1.4765e-02-0.2249image
ENSG00000244754.7,N4BP2L2CESCEAGB_cells_memory7.8979e-030.2168image
chr13:32524776-32525685:-CHOLEERNK_cells_activated1.7241e-020.4814image
ENSG00000244754.7,N4BP2L2CHOLEAGB_cells_memory3.3707e-020.4025image
chr13:32524776-32525685:-COADEERDendritic_cells_activated1.0087e-020.1882image
ENSG00000244754.7,N4BP2L2COADEAGNK_cells_resting8.2473e-03-0.1922image
chr13:32500888-32503139:-ESCAEERNK_cells_activated8.8416e-040.4250image
chr13:32514541-32516066:-ESCAEERMonocytes1.6782e-02-0.2980image
chr13:32524776-32525685:-ESCAEEREosinophils2.9939e-030.2362image
ENSG00000244754.7,N4BP2L2ESCAEAGEosinophils1.0413e-030.2569image
chr13:32514541-32516066:-GBMEERPlasma_cells3.8478e-02-0.2223image
chr13:32524776-32525685:-KICHEERPlasma_cells1.5644e-030.6210image
ENSG00000244754.7,N4BP2L2KICHEAGT_cells_CD84.8816e-060.7772image
chr13:32514541-32516066:-KIRCEERB_cells_naive2.8066e-020.1710image
chr13:32524776-32525685:-KIRCEERMacrophages_M25.3048e-04-0.2069image
ENSG00000244754.7,N4BP2L2KIRCEAGB_cells_naive2.8415e-020.1257image
chr13:32514541-32516066:-KIRPEERT_cells_CD82.1746e-030.4707image
chr13:32524776-32525685:-KIRPEERT_cells_CD4_memory_activated1.3814e-030.2539image
ENSG00000244754.7,N4BP2L2KIRPEAGT_cells_CD4_memory_activated4.6910e-020.1504image
chr13:32514541-32516066:-LGGEERT_cells_regulatory_(Tregs)1.2286e-030.1688image
chr13:32524776-32525685:-LGGEERMacrophages_M12.3598e-02-0.1365image
chr13:32524776-32525685:-LIHCEEREosinophils1.5749e-030.3843image
ENSG00000244754.7,N4BP2L2LIHCEAGEosinophils4.4027e-030.3025image
chr13:32514541-32516066:-LUADEERT_cells_CD83.3071e-030.4076image
chr13:32524776-32525685:-LUADEERT_cells_CD4_memory_resting7.5205e-04-0.1811image
ENSG00000244754.7,N4BP2L2LUADEAGT_cells_CD4_memory_resting4.6652e-03-0.1496image
chr13:32514541-32516066:-LUSCEERT_cells_CD4_memory_resting2.8229e-020.4573image
ENSG00000244754.7,N4BP2L2MESOEAGNeutrophils3.1302e-020.3179image
chr13:32524776-32525685:-OVEERB_cells_memory3.2533e-020.1771image
ENSG00000244754.7,N4BP2L2OVEAGB_cells_memory1.5183e-020.1670image
ENSG00000244754.7,N4BP2L2PAADEAGDendritic_cells_activated3.7877e-020.1802image
chr13:32524776-32525685:-PCPGEERNK_cells_activated9.1091e-03-0.2750image
ENSG00000244754.7,N4BP2L2PCPGEAGNK_cells_activated2.5674e-02-0.1913image
chr13:32524776-32525685:-PRADEERMast_cells_resting9.9549e-060.2648image
ENSG00000244754.7,N4BP2L2PRADEAGMast_cells_resting1.1797e-040.2073image
chr13:32524776-32525685:-READEERPlasma_cells1.2987e-020.2935image
ENSG00000244754.7,N4BP2L2READEAGT_cells_gamma_delta2.8130e-020.2536image
chr13:32524776-32525685:-SARCEERT_cells_gamma_delta4.9004e-02-0.2553image
chr13:32514541-32516066:-SKCMEERB_cells_naive2.9708e-020.2857image
chr13:32524776-32525685:-SKCMEERNeutrophils1.5628e-030.2154image
ENSG00000244754.7,N4BP2L2SKCMEAGNeutrophils4.4629e-030.1845image
chr13:32492966-32494556:-STADEERMacrophages_M01.8265e-020.3670image
chr13:32500888-32503139:-STADEERMacrophages_M24.7066e-020.1712image
chr13:32510517-32510790:-STADEERT_cells_gamma_delta4.0849e-020.1818image
chr13:32524776-32525685:-STADEERNK_cells_activated1.4957e-030.1802image
chr13:32532627-32533756:-STADEERMast_cells_activated3.2798e-020.3340image
ENSG00000244754.7,N4BP2L2STADEAGT_cells_CD81.1207e-020.1376image
ENSG00000244754.7,N4BP2L2TGCTEAGMacrophages_M21.7551e-020.3057image
chr13:32514541-32516066:-THCAEERMacrophages_M14.9191e-02-0.1372image
chr13:32524776-32525685:-THCAEERT_cells_regulatory_(Tregs)1.4478e-030.1699image
ENSG00000244754.7,N4BP2L2THCAEAGMacrophages_M14.0254e-02-0.0995image
chr13:32524776-32525685:-THYMEERT_cells_CD83.3476e-020.3212image
chr13:32524776-32525685:-UCECEEREosinophils3.6300e-02-0.3604image
chr13:32524776-32525685:-UVMEERT_cells_gamma_delta3.9279e-020.3989image
ENSG00000244754.7,N4BP2L2UVMEAGT_cells_gamma_delta4.2288e-020.3935image


Top

6. Enriched editing regions and immune gene sets for N4BP2L2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr13:32524776-32525685:-BRCAEER4.0797e-02image8.7801e-030.0954image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000244754.7,N4BP2L2BRCAEAG1.9072e-110.23383.0479e-070.17941.8991e-050.15025.6432e-040.1214image
chr13:32524776-32525685:-BRCAEER2.0965e-100.22879.5900e-070.17731.0018e-050.16011.3663e-050.1577image
chr13:32524776-32525685:-ESCAEER1.7091e-040.29656.2036e-030.21821.1439e-030.25813.0601e-020.1732image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000244754.7,N4BP2L2ACCGSVA_HALLMARK_DNA_REPAIREAG1.1513e-030.6343image
chr13:32524776-32525685:-BLCAGSVA_HALLMARK_COAGULATIONEER5.9308e-030.2275image
ENSG00000244754.7,N4BP2L2BLCAGSVA_HALLMARK_UV_RESPONSE_UPEAG5.7159e-040.2522image
ENSG00000244754.7,N4BP2L2BRCAGSVA_HALLMARK_UV_RESPONSE_UPEAG2.1740e-110.2332image
chr13:32514541-32516066:-BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEER2.0022e-030.2151image
chr13:32524776-32525685:-BRCAGSVA_HALLMARK_UV_RESPONSE_UPEER8.3344e-150.2776image
chr13:32524776-32525685:-CESCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER8.4334e-040.3045image
ENSG00000244754.7,N4BP2L2CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.5233e-04-0.3054image
chr13:32524776-32525685:-CHOLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.4200e-02-0.4338image
ENSG00000244754.7,N4BP2L2COADGSVA_HALLMARK_GLYCOLYSISEAG3.9754e-040.2557image
chr13:32524776-32525685:-COADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.8585e-030.2109image
chr13:32500888-32503139:-ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.0318e-020.3343image
chr13:32524776-32525685:-ESCAGSVA_HALLMARK_DNA_REPAIREER1.2874e-060.3763image
ENSG00000244754.7,N4BP2L2ESCAGSVA_HALLMARK_MYC_TARGETS_V1EAG3.6181e-040.2785image
chr13:32514541-32516066:-ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEER2.9648e-030.3657image
chr13:32524776-32525685:-GBMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.2070e-020.2812image
ENSG00000244754.7,N4BP2L2HNSCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.7703e-020.2283image
chr13:32524776-32525685:-KICHGSVA_HALLMARK_UV_RESPONSE_DNEER1.7683e-03-0.6156image
chr13:32514541-32516066:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.1723e-02-0.1673image
chr13:32524776-32525685:-KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.0413e-080.3354image
ENSG00000244754.7,N4BP2L2KIRCGSVA_HALLMARK_COAGULATIONEAG9.5715e-090.3216image
chr13:32524776-32525685:-KIRPGSVA_HALLMARK_UV_RESPONSE_DNEER1.4075e-02-0.1963image
ENSG00000244754.7,N4BP2L2KIRPGSVA_HALLMARK_UV_RESPONSE_UPEAG2.1910e-030.2301image
ENSG00000244754.7,N4BP2L2LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEAG9.0755e-03-0.2124image
chr13:32524776-32525685:-LAMLGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.1549e-020.2057image
chr13:32524776-32525685:-LGGGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.0691e-030.1727image
chr13:32514541-32516066:-LGGGSVA_HALLMARK_APICAL_SURFACEEER3.5977e-030.1522image
ENSG00000244754.7,N4BP2L2LGGGSVA_HALLMARK_ADIPOGENESISEAG3.4695e-050.1941image
chr13:32514541-32516066:-LUADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER7.5192e-050.5301image
chr13:32524776-32525685:-LUADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.1928e-060.2432image
ENSG00000244754.7,N4BP2L2LUADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.8248e-060.2421image
chr13:32524776-32525685:-LUSCGSVA_HALLMARK_MTORC1_SIGNALINGEER5.2093e-040.2196image
chr13:32514541-32516066:-LUSCGSVA_HALLMARK_HYPOXIAEER4.5399e-020.4211image
ENSG00000244754.7,N4BP2L2LUSCGSVA_HALLMARK_MTORC1_SIGNALINGEAG2.7154e-040.2219image
chr13:32524776-32525685:-MESOGSVA_HALLMARK_NOTCH_SIGNALINGEER2.4056e-020.3562image
chr13:32524776-32525685:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER9.7282e-050.3169image
chr13:32524776-32525685:-PAADGSVA_HALLMARK_HYPOXIAEER3.1798e-020.1929image
ENSG00000244754.7,N4BP2L2PAADGSVA_HALLMARK_COAGULATIONEAG4.0776e-020.1777image
ENSG00000244754.7,N4BP2L2PCPGGSVA_HALLMARK_COAGULATIONEAG3.3985e-030.2495image
chr13:32514541-32516066:-PCPGGSVA_HALLMARK_P53_PATHWAYEER2.5406e-02-0.3013image
chr13:32524776-32525685:-PCPGGSVA_HALLMARK_SPERMATOGENESISEER1.1704e-020.2662image
chr13:32524776-32525685:-PRADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER8.0032e-050.2373image
ENSG00000244754.7,N4BP2L2PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.4627e-080.2967image
chr13:32523220-32523647:-PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER8.8983e-030.2616image
ENSG00000244754.7,N4BP2L2SARCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG4.1818e-040.3566image
chr13:32524776-32525685:-SARCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER8.6127e-030.3363image
ENSG00000244754.7,N4BP2L2SKCMGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.7272e-02-0.1357image
chr13:32524776-32525685:-SKCMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER4.1423e-030.1957image
chr13:32532627-32533756:-STADGSVA_HALLMARK_P53_PATHWAYEER3.0361e-030.4516image
chr13:32524776-32525685:-STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.1321e-110.3584image
chr13:32500888-32503139:-STADGSVA_HALLMARK_HYPOXIAEER1.1475e-050.3677image
chr13:32492966-32494556:-STADGSVA_HALLMARK_GLYCOLYSISEER9.4857e-030.4004image
chr13:32514541-32516066:-STADGSVA_HALLMARK_ADIPOGENESISEER6.5701e-030.2320image
chr13:32510517-32510790:-STADGSVA_HALLMARK_HYPOXIAEER7.8636e-040.2942image
ENSG00000244754.7,N4BP2L2STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.9909e-070.2779image
ENSG00000244754.7,N4BP2L2TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG8.8037e-040.4183image
chr13:32524776-32525685:-THCAGSVA_HALLMARK_GLYCOLYSISEER2.4169e-120.3635image
ENSG00000244754.7,N4BP2L2THCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.5206e-120.3310image
chr13:32524776-32525685:-THYMGSVA_HALLMARK_PEROXISOMEEER1.1294e-030.4748image
chr13:32514541-32516066:-THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER3.6363e-03-0.4991image
ENSG00000244754.7,N4BP2L2THYMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.4268e-040.3718image
ENSG00000244754.7,N4BP2L2UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.1523e-020.3296image
chr13:32524776-32525685:-UCECGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER3.9503e-040.5732image
ENSG00000244754.7,N4BP2L2UCSGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.8471e-02-0.4422image


Top

7. Enriched editing regions and drugs for N4BP2L2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000244754.7,N4BP2L2ACCLFM.A13EAG2.9462e-020.4542image
chr13:32524776-32525685:-BLCACGP.60474EER3.2341e-05-0.3379image
chr13:32514541-32516066:-BLCABMS.708163EER8.5585e-030.4790image
ENSG00000244754.7,N4BP2L2BLCACGP.60474EAG3.8760e-03-0.2125image
ENSG00000244754.7,N4BP2L2BRCACCT007093EAG3.1438e-110.2313image
chr13:32514541-32516066:-BRCAIPA.3EER9.6457e-030.1813image
chr13:32524776-32525685:-BRCACCT007093EER1.5906e-090.2175image
chr13:32524776-32525685:-CESCCMKEER3.4839e-03-0.2680image
chr13:32514541-32516066:-CESCJNK.Inhibitor.VIIIEER1.9102e-02-0.4952image
ENSG00000244754.7,N4BP2L2CESCA.770041EAG2.3760e-11-0.5125image
ENSG00000244754.7,N4BP2L2CHOLAZ628EAG2.3422e-04-0.6415image
chr13:32524776-32525685:-CHOLBleomycinEER2.1068e-02-0.4681image
ENSG00000244754.7,N4BP2L2COADLenalidomideEAG2.9798e-030.2155image
chr13:32524776-32525685:-COADBIRB.0796EER4.3430e-030.2082image
chr13:32500888-32503139:-ESCAJNJ.26854165EER6.5138e-03-0.3563image
ENSG00000244754.7,N4BP2L2ESCAElesclomolEAG3.0172e-04-0.2821image
chr13:32514541-32516066:-ESCAJNJ.26854165EER1.0629e-020.3173image
chr13:32524776-32525685:-ESCADocetaxelEER4.8712e-06-0.3567image
chr13:32514541-32516066:-GBMCCT018159EER1.3825e-020.2631image
chr13:32524776-32525685:-GBMKIN001.135EER3.9940e-04-0.3887image
ENSG00000244754.7,N4BP2L2GBMFTI.277EAG1.6991e-020.2194image
ENSG00000244754.7,N4BP2L2HNSCDMOGEAG4.3513e-030.2931image
chr13:32524776-32525685:-HNSCJNK.Inhibitor.VIIIEER1.4881e-020.2665image
chr13:32524776-32525685:-KICHBAY.61.3606EER2.4214e-030.6010image
ENSG00000244754.7,N4BP2L2KICHKU.55933EAG6.0508e-08-0.8531image
chr13:32514541-32516066:-KIRCBicalutamideEER3.8676e-03-0.2237image
ENSG00000244754.7,N4BP2L2KIRCA.770041EAG2.4140e-06-0.2666image
chr13:32524776-32525685:-KIRCBortezomibEER5.1563e-06-0.2700image
chr13:32514541-32516066:-KIRPFH535EER3.7923e-020.3294image
chr13:32524776-32525685:-KIRPBAY.61.3606EER2.5226e-040.2891image
ENSG00000244754.7,N4BP2L2KIRPBryostatin.1EAG5.9668e-08-0.3957image
ENSG00000244754.7,N4BP2L2LAMLA.770041EAG5.7688e-06-0.3607image
chr13:32524776-32525685:-LAMLA.770041EER4.2134e-08-0.4293image
ENSG00000244754.7,N4BP2L2LGGATRAEAG4.4236e-030.1341image
chr13:32514541-32516066:-LGGGW.441756EER1.0874e-02-0.1333image
chr13:32524776-32525685:-LGGAP.24534EER4.7535e-030.1698image
chr13:32524776-32525685:-LIHCLenalidomideEER2.2347e-020.2830image
ENSG00000244754.7,N4BP2L2LUADElesclomolEAG1.9448e-03-0.1637image
chr13:32514541-32516066:-LUADCGP.60474EER6.8897e-03-0.3774image
chr13:32524776-32525685:-LUADKIN001.135EER8.2997e-04-0.1797image
ENSG00000244754.7,N4BP2L2LUSCErlotinibEAG1.2175e-03-0.1977image
chr13:32524776-32525685:-LUSCErlotinibEER3.3716e-03-0.1862image
chr13:32514541-32516066:-LUSCCGP.60474EER1.2205e-02-0.5135image
ENSG00000244754.7,N4BP2L2MESOA.443654EAG4.8970e-02-0.2920image
chr13:32524776-32525685:-MESOA.443654EER1.4781e-02-0.3828image
ENSG00000244754.7,N4BP2L2OVGDC0941EAG1.3338e-02-0.1701image
chr13:32524776-32525685:-OVEmbelinEER3.3026e-040.2931image
chr13:32514541-32516066:-OVAKT.inhibitor.VIIIEER9.3606e-03-0.3385image
ENSG00000244754.7,N4BP2L2PAADGNF.2EAG1.7488e-03-0.2719image
chr13:32524776-32525685:-PAADGNF.2EER1.7130e-05-0.3800image
chr13:32514541-32516066:-PCPGJNK.Inhibitor.VIIIEER2.7497e-02-0.2973image
ENSG00000244754.7,N4BP2L2PCPGBMS.536924EAG5.4302e-05-0.3389image
chr13:32524776-32525685:-PCPGAUY922EER1.9671e-020.2469image
chr13:32524776-32525685:-PRADCCT007093EER1.9574e-040.2244image
chr13:32523220-32523647:-PRADLFM.A13EER3.9990e-020.2068image
ENSG00000244754.7,N4BP2L2PRADBryostatin.1EAG3.0502e-10-0.3329image
ENSG00000244754.7,N4BP2L2READBIRB.0796EAG1.7425e-020.2739image
chr13:32524776-32525685:-READBIRB.0796EER2.9599e-030.3478image
chr13:32514541-32516066:-SARCAKT.inhibitor.VIIIEER5.2969e-030.4612image
ENSG00000244754.7,N4BP2L2SARCDocetaxelEAG7.1494e-05-0.3979image
chr13:32524776-32525685:-SARCCCT007093EER1.0985e-020.3262image
ENSG00000244754.7,N4BP2L2SKCMGSK269962AEAG9.8815e-03-0.1691image
chr13:32524776-32525685:-SKCMGSK269962AEER6.5323e-04-0.2339image
chr13:32500888-32503139:-STADFTI.277EER2.1455e-05-0.3569image
chr13:32524776-32525685:-STADBMS.509744EER9.1396e-09-0.3201image
chr13:32492966-32494556:-STADKU.55933EER1.2964e-020.3849image
ENSG00000244754.7,N4BP2L2STADBMS.509744EAG1.1038e-05-0.2362image
chr13:32510517-32510790:-STADDocetaxelEER1.1009e-03-0.2863image
chr13:32514541-32516066:-STADAKT.inhibitor.VIIIEER2.8801e-02-0.1875image
chr13:32532627-32533756:-STADCI.1040EER2.0993e-03-0.4667image
ENSG00000244754.7,N4BP2L2TGCTAZD8055EAG9.4720e-040.4160image
ENSG00000244754.7,N4BP2L2THCAA.770041EAG1.1170e-12-0.3364image
chr13:32524776-32525685:-THCACI.1040EER2.2285e-07-0.2729image
chr13:32524776-32525685:-THYMBMS.509744EER1.9147e-03-0.4550image
chr13:32514541-32516066:-THYMDocetaxelEER9.5522e-03-0.4512image
ENSG00000244754.7,N4BP2L2THYMAKT.inhibitor.VIIIEAG6.4352e-030.2806image
chr13:32524776-32525685:-UCECBortezomibEER1.0245e-04-0.6168image
ENSG00000244754.7,N4BP2L2UCECBortezomibEAG1.4423e-03-0.4088image
chr13:32524776-32525685:-UVMEmbelinEER1.4767e-020.4640image
ENSG00000244754.7,N4BP2L2UVMEmbelinEAG1.5618e-020.4606image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType